Skip to main content
Erschienen in:

17.04.2020 | Dabigatran

The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm

verfasst von: E. Rota, L. Testa, G. Di Brigida, S. Agosti, M. E. Rovere, R. Risso, N. Morelli

Erschienen in: Journal of Thrombosis and Thrombolysis | Ausgabe 3/2020

Einloggen, um Zugang zu erhalten

Abstract

Approximately 1–2% of patients with non-valvular atrial fibrillation have an acute ischemic stroke (AIS) while on direct oral anticoagulant (DOAC) treatment every year. However, current evidence on stroke subtypes, pathophysiology and factors leading to the failure of DOAC preventive therapy in a “real world” setting is still scanty. This study aimed at investigating whether there is any relationship between DOAC plasma levels and the stroke occurrence, on the basis of the phenotypic classification and pathophysiology of the stroke, in a cohort of DOAC-treated patients admitted to our hospital for AIS over 1-year period. A total of 28 patients had DOAC plasma levels determined in emergency and were included in the study, nine patients receiving dabigatran, 11 rivaroxaban and 8 apixaban. The DOAC levels were low in 8/28 patients (28.6% of the sample), intermediate in 4 (14.3%) and high in 16 (57.1%). The most prevalent stroke subtype was the small vessel disease, according to the A-S-C-O phenotypic classification, in 53.6% of our sample. The most common clinical presentation was “minor stroke” in 71.4% of the cases. There was a significantly higher proportion of patients with high DOAC levels in the small vessel group, compared to the cardioembolic group without other phenotypes. The question arises as to the most suitable clinical management of AIS in these patients on DOACs. In the current absence of clear evidence, taking into account the DOAC levels (low/intermediate/high) and the underlying stroke pathophysiology, we present a flowchart of our proposed clinical management of ischemic stroke in patients while on DOAC.
Literatur
1.
Zurück zum Zitat Meinel TR, Frey S, Arnold M, Kendroud S, Fischer U, Kaesmacher J, Heldner MR, Jung S (2019) Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants—a systematic review. PLoS ONE 14(3):e0213379CrossRef Meinel TR, Frey S, Arnold M, Kendroud S, Fischer U, Kaesmacher J, Heldner MR, Jung S (2019) Clinical presentation, diagnostic findings and management of cerebral ischemic events in patients on treatment with non-vitamin K antagonist oral anticoagulants—a systematic review. PLoS ONE 14(3):e0213379CrossRef
2.
Zurück zum Zitat Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C et al (2016) Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 137:178–183CrossRef Testa S, Tripodi A, Legnani C, Pengo V, Abbate R, Dellanoce C et al (2016) Plasma levels of direct oral anticoagulants in real life patients with atrial fibrillation: results observed in four anticoagulation clinics. Thromb Res 137:178–183CrossRef
3.
Zurück zum Zitat Kanuri SH, Kreutz RP (2019) Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 9(1):E7CrossRef Kanuri SH, Kreutz RP (2019) Pharmacogenomics of novel direct oral anticoagulants: newly identified genes and genetic variants. J Pers Med 9(1):E7CrossRef
4.
Zurück zum Zitat Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B et al (2018) Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 16(5):842–848CrossRef Testa S, Paoletti O, Legnani C, Dellanoce C, Antonucci E, Cosmi B et al (2018) Low drug levels and thrombotic complications in high-risk atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 16(5):842–848CrossRef
5.
Zurück zum Zitat Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Coordinator of START2-Register et al (2019) Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 17(7):1064–1072CrossRef Testa S, Legnani C, Antonucci E, Paoletti O, Dellanoce C, Cosmi B, Coordinator of START2-Register et al (2019) Drug levels and bleeding complications in atrial fibrillation patients treated with direct oral anticoagulants. J Thromb Haemost 17(7):1064–1072CrossRef
6.
Zurück zum Zitat Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11:756–760CrossRef Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W (2013) Measuring oral direct inhibitors (ODIs) of thrombin and factor Xa: a recommendation from the subcommittee on control of anticoagulation of the scientific and standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost 11:756–760CrossRef
7.
Zurück zum Zitat Rota E, Agosti S, Risso R, Morelli N (2019) Lumbar puncture after direct oral anticoagulant (DOAC) reversal: a proposed algorithm for the emergency department. Intern Emerg Med 14(7):1175–1179CrossRef Rota E, Agosti S, Risso R, Morelli N (2019) Lumbar puncture after direct oral anticoagulant (DOAC) reversal: a proposed algorithm for the emergency department. Intern Emerg Med 14(7):1175–1179CrossRef
8.
Zurück zum Zitat Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E et al (2018) Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT). Eur J Neurol. https://doi.org/10.1111/ene.13582CrossRefPubMed Touzé E, Gruel Y, Gouin-Thibault I, De Maistre E et al (2018) Intravenous thrombolysis for acute ischaemic stroke in patients on direct oral anticoagulants. Expert opinion of the Societe Francaise de Neurologie Vasculaire (SFNV) and the Groupe Francais d'etudes sur l'Hemostase et la Thrombose (GFHT). Eur J Neurol. https://​doi.​org/​10.​1111/​ene.​13582CrossRefPubMed
9.
Zurück zum Zitat Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, ESC Scientific Document Group et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393CrossRef Steffel J, Verhamme P, Potpara TS, Albaladejo P, Antz M, Desteghe L, ESC Scientific Document Group et al (2018) The 2018 European Heart Rhythm Association Practical Guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Eur Heart J 39(16):1330–1393CrossRef
10.
Zurück zum Zitat Macha K, Marsch A, Siedler G, Breuer L, Strasser EF, Engelhorn T, Schwab S, Kallmünzer B (2019) Cerebral ischemia in patients on direct oral anticoagulants. Stroke 50(4):873–879CrossRef Macha K, Marsch A, Siedler G, Breuer L, Strasser EF, Engelhorn T, Schwab S, Kallmünzer B (2019) Cerebral ischemia in patients on direct oral anticoagulants. Stroke 50(4):873–879CrossRef
11.
Zurück zum Zitat Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG (2009) New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 27:502–508CrossRef Amarenco P, Bogousslavsky J, Caplan LR, Donnan GA, Hennerici MG (2009) New approach to stroke subtyping: the A-S-C-O (phenotypic) classification of stroke. Cerebrovasc Dis 27:502–508CrossRef
12.
Zurück zum Zitat Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67–74CrossRef Morisky DE, Green LW, Levine DM (1986) Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care 24(1):67–74CrossRef
13.
Zurück zum Zitat Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C et al (2017) Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc 6:e007034CrossRef Paciaroni M, Agnelli G, Falocci N, Tsivgoulis G, Vadikolias K, Liantinioti C et al (2017) Early recurrence and major bleeding in patients with acute ischemic stroke and atrial fibrillation treated with non-vitamin K oral anticoagulants (RAF-NOACs) study. J Am Heart Assoc 6:e007034CrossRef
14.
Zurück zum Zitat Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94(6):697–709CrossRef Cuker A, Burnett A, Triller D, Crowther M, Ansell J, Van Cott EM, Wirth D, Kaatz S (2019) Reversal of direct oral anticoagulants: guidance from the anticoagulation forum. Am J Hematol 94(6):697–709CrossRef
15.
Zurück zum Zitat Rota E, Agosti S, Risso R, Morelli N (2018) Thrombolysis on direct oral anticoagulants: the 'grey area'. Eur J Neurol 25(6):e63CrossRef Rota E, Agosti S, Risso R, Morelli N (2018) Thrombolysis on direct oral anticoagulants: the 'grey area'. Eur J Neurol 25(6):e63CrossRef
16.
Zurück zum Zitat Cappellari M, Bovi P (2017) Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series. J Thromb Thrombolysis 43:248–251CrossRef Cappellari M, Bovi P (2017) Continuation of direct oral anticoagulants in the acute phase of ischemic stroke. A case series. J Thromb Thrombolysis 43:248–251CrossRef
17.
Zurück zum Zitat Sakamoto Y, Okubo S, Nito C, Suda S, Matsumoto N, Abe A et al (2017) The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. Eur J Neurol 24:1399–1406CrossRef Sakamoto Y, Okubo S, Nito C, Suda S, Matsumoto N, Abe A et al (2017) The relationship between stroke severity and prior direct oral anticoagulant therapy in patients with acute ischaemic stroke and non-valvular atrial fibrillation. Eur J Neurol 24:1399–1406CrossRef
18.
Zurück zum Zitat Wilson D, Werring DJ (2017) Antithrombotic therapy in patients with cerebral microbleeds. Curr Opin Neurol 30(1):38–47CrossRef Wilson D, Werring DJ (2017) Antithrombotic therapy in patients with cerebral microbleeds. Curr Opin Neurol 30(1):38–47CrossRef
Metadaten
Titel
The management of patients with acute ischemic stroke while on direct oral anticoagulants (DOACs): data from an Italian cohort and a proposed algorithm
verfasst von
E. Rota
L. Testa
G. Di Brigida
S. Agosti
M. E. Rovere
R. Risso
N. Morelli
Publikationsdatum
17.04.2020
Verlag
Springer US
Erschienen in
Journal of Thrombosis and Thrombolysis / Ausgabe 3/2020
Print ISSN: 0929-5305
Elektronische ISSN: 1573-742X
DOI
https://doi.org/10.1007/s11239-020-02108-5

Kompaktes Leitlinien-Wissen Innere Medizin (Link öffnet in neuem Fenster)

Mit medbee Pocketcards schnell und sicher entscheiden.
Leitlinien-Wissen kostenlos und immer griffbereit auf ihrem Desktop, Handy oder Tablet.

Neu im Fachgebiet Innere Medizin

Podcast

Magendarminfekte: Dos and Don'ts bei Kleinkindern

Die Leitlinie zur akuten infektiösen Gastroenteritis wurde 2024 umfassend überarbeitet. Cola und Saft zur oralen Hydratation und einige Antidiarrhoika sollten vermieden werden. Von einem standardmäßigen Erregerpanel wird abgeraten. Die Hintergründe zu diesen und weiteren Empfehlungen erläutert Leitlinienkoordinator Prof. Carsten Posovszky.

Körperlich fitte Krebskranke leben länger

Krebspatienten, auch und vor allem solche in fortgeschrittenen Stadien, profitieren offenbar von guter körperlicher Verfassung. Hohe Muskelkraft und kardiorespiratorische Fitness sind laut Ergebnissen einer Metaanalyse mit geringerer Mortalität assoziiert.

Vorhofflimmern: Antikoagulation vor Schlaganfall von Vorteil

Erleiden Menschen mit Vorhofflimmern einen ischämischen Schlaganfall, ist dieser weniger schwer, auch sind Infarktgröße und Blutungsrisiko geringer, wenn sie zuvor orale Antikoagulanzien erhalten haben. Die Art der Antikoagulation spielt dabei keine Rolle.

HCL-Systeme bei Typ-1-Diabetes: Blutzuckerkontrolle besser, Risiko für Ketoazidose aber höher

Eine bessere Blutzuckerkontrolle und weniger Fälle von hypoglykämischem Koma, dafür mehr diabetische Ketoazidosen. Dieses HCL-Insulin-Therapie-Profil zeigte sich in einem Vergleich von Hybrid-Closed-Loop(HCL)- und Open-Loop-Systemen bei Typ-I-Diabetes im DPV-Register.

EKG Essentials: EKG befunden mit System (Link öffnet in neuem Fenster)

In diesem CME-Kurs können Sie Ihr Wissen zur EKG-Befundung anhand von zwölf Video-Tutorials auffrischen und 10 CME-Punkte sammeln.
Praxisnah, relevant und mit vielen Tipps & Tricks vom Profi.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.